Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by jdstoxon Jan 17, 2018 2:16pm
173 Views
Post# 27378517

RE:RE:RE:RE:Reality quips...

RE:RE:RE:RE:Reality quips... Share price is always the sum of collected investor opinion, roadking08, no matter how that opinion has been influenced. This forum is too often not helpful.

One other important point - this BoD and management has had control for only 4 months, since late September. The argument can be made that the full vision for the advancement of Bioasis could only be started as of December 4th with the resignations of the last 3 long term directors.

Whining in front of this team or otherwise rubbing their faces in our history is wrong.

I cannot speak for the BoD or management in any way on this. Rather, it should be obvious to you all that the new BoD and management can not, should not and (I expect) will not accept any responsibility for that history.

It's wrong, irresponsible, optically damaging and, frankly, kinda weird and stupid to hold their feet to the fire on this.

Leave them alone. Expect professionals like this to run the company in ways similar to the worlds they come from, the pharma and academic worlds of extraordinary work ethics (they're all PhDs and MDs!!!), high personal accomplishment, secret skunkworks and almost perfect success rates. (Stagliano, 3 for 3 with deals; Radhakrishnan with an astonishing clinical record and still found time to master Russian; Deborah Rathjen, noted pharma corporate leader, so needed by Bioasis; Mark Day, experienced, working fool, fearless; Mei Mei Tian with unparalled BBB knowledge and experience; Chris Lowe, can you spell $; and a number of other scientists who are already hard at work.)

And none of them had anything to do with the last 7 years.

Get behind them.

jdstox

Bullboard Posts